CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS

PURPOSE: Vascular endothelial growth factor (VEGF) is upregulated in glioblastoma and may contribute to immunosuppression. We performed a phase 2 study of pembrolizumab, a programmed death-1 (PD-1) blocking antibody alone or with the anti-VEGF antibody bevacizumab in recurrent glioblastoma with deta...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Reardon, David, Molinaro, Annette, Peters, Katherine, Clarke, Jennifer, Jordan, Justin, de Groot, John, Nghiemphu, Phioanh, Kaley, Thomas, Colman, Howard, McCluskey, Christine, Smith, Timothy, Cote, David, Severgnini, Mariano, Yearley, Jennifer, Zhao, Qing, Blumenschein, Wendy, Duda, Gabriel, Muzikansky, Alona, Jain, Rakesh, Wen, Patrick, Nayak, Lakshmi
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2020
Aiheet:
Clinical Trials: Immunologic
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650927/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.166
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia